H.C. Wainwright Reiterates Buy Rating on Can-Fite BioPharma (CANF)

September 29, 2026 6:49 AM EDT Send to a Friend
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $8.00 price target on Can-Fite BioPharma (NYSE: CANF).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login